Quality of life of patients with cardiomyopathy treated with sacubitril/ valsartan vs. standard therapy during or after COVID-19 in Kazakhstan

The objective of this study is to evaluate the quality of life (QoL) of hospitalised patients with cardiomyopathy (CM) treated with a fixed dose combination (FDC) of sacubitril/valsartan, or standard therapy in Kazakhstan during or after COVID-19. This is an observational study of patients with incidents of CM that require hospitalisation during or after a COVID-19 infection. QoL was evaluated with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) during admission. Demographic and other characteristics of the patients were analysed for both patient groups: on standard therapy and on FDC therapy with sacubitril/valsartan. Patients on standard therapy tended to be older and had a higher relative share of previous cardiac surgery. The vaccination rate is low in general and was lower in the group on standard therapy. The QoL between the two groups was significantly higher in the group on FDC therapy. No statistically significant difference in the QoL between males and females was found. The vaccination status also does not influence the QoL. Patients with prior surgery possess a higher quality of life. QoL in younger patients is higher. There is a statistically significant negative correlation between age and QoL, and with the increase in age over one year, the quality of life will decrease by 0.3622 points. Sacubitril/valsartan is associated with higher QoL in hospitalised patients with CM during or after COVID-19. QoL is correlated with age. Vaccination does not affect QoL, but patients with prior cardiac surgeries possess a higher QoL.